Increased risk of angiosarcoma secondary to cancer radiotherapy: Case series and review of the treatment options.
angiosarcoma
breast-conserving therapy
radiation
Journal
Dermatologic therapy
ISSN: 1529-8019
Titre abrégé: Dermatol Ther
Pays: United States
ID NLM: 9700070
Informations de publication
Date de publication:
03 2020
03 2020
Historique:
received:
01
08
2019
revised:
24
11
2019
accepted:
25
01
2020
pubmed:
31
1
2020
medline:
15
5
2021
entrez:
31
1
2020
Statut:
ppublish
Résumé
Angiosarcomas (ASs) are aggressive tumors of vascular endothelial origin, occurring sporadically or in association with prior radiotherapy or chronic lymphedema. With only 1-5% of all sarcomas, the incidence seems low, but for the affected patient due to the extremely poor prognosis and the limited treatment options, the fate is often inevitable. Radiotherapy, chemotherapy, or "target therapy" have been used in the management of AS, but represent individual case decisions without lasting evidence. Over the past few years, breast-conserving surgery followed by radiation therapy, known as breast-conserving therapy (BCT), is being employed as a standard treatment for early-stage breast cancer, but there has been an increase in reports of AS following BCT. We report two cases of AS following BCT and one case of primary AS involving the lower limb.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13234Informations de copyright
© 2020 Wiley Periodicals, Inc.
Références
Agulnik, M., Yarber, J. L., Okuno, S. H., Von Mehren, M., Jovanovic, B. D., & Brockstein, B. E. (2012). An open-label, multicenter, phase II study of bevacizumab for the treatment of angiosarcoma and epithelioid hemangioendotheliomas. Annals of Oncology, 24(1), 257-263.
Billings, S. D., McKenney, J. K., Folpe, A. L., Hardacre, M. C., & Weiss, S. W. (2004). Cutaneous angiosarcoma following breast-conserving surgery and radiation: An analysis of 27 cases. American Journal of Surgical Pathology, 28, 781-788.
Brenn, T., & Fletcher, C. D. (2005). Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: Clinicopathologic analysis of 42 cases. American Journal of Surgical Pathology, 29(8), 983-996.
Chow, W., Amaya, C. N., Rains, S., Chow, M., Dickerson, E. B., & Bryan, B. A. (2015). Growth attenuation of cutaneous angiosarcoma with propranolol-mediated β-blockade. JAMA Dermatology, 151(11), 1226-1229.
D'Angelo, S. P., Antonescu, C. R., Kuk, D., Qin, L., Moraco, N., & Carvajal, R. C. (2013). High-risk features in radiation-associated breast angiosarcomas. British Journal of Cancer, 109, 2340-2346.
Feigenberg, S. J., Mendenhall, N. P., Reith, J. D., Ward, J. R., & Copeland, E. M., III. (2002). Angiosarcoma after breast-conserving therapy: Experience with hyperfractionatedradiotherapy. International Journal of Radiation, Oncology, Biology, Physics, 52, 620-626.
Giardino, R., Fini, M., Bonazzi, V., Cadossi, R., Nicolini, A., & Carpi, A. (2006). Electrochemotherapy a novel approach to the treatment of metastatic nodules on the skin and subcutaneous tissues. Biomedicine & Pharmacotherapy, 60(8), 458-462.
Kinard, J. D., Zwicker, R. D., Schmidt-Ullrich, R. K., Kaufman, N., & Pieters, R. (1996). Total craniofacial photon shell technique for radiotherapy of extensive angiosarcomas of the head. The British Journal of Radiology, 69(820), 351-355.
Kollár, A., Jones, R. L., Stacchiotti, S., Gelderblom, H., Guida, M., & Grignani, G. (2017). Pazopanib in advanced vascular sarcomas: An EORTC Soft Tissue and Bone Sarcoma Group (STBSG) retrospective analysis. Acta Oncologica, 56(1), 88-92.
Le Cesne, A., Ray-Coquard, I., Duffaud, F., Chevreau, C., Penel, N., & Nguyen, B. B. (2015). Trabectedin in patients with advanced soft tissue sarcoma: A retrospective national analysis of the French Sarcoma Group. European Journal of Cancer, 51(6), 742-750.
Lyou, Y., Barber, E., Mehta, R., Lee, T., Goreal, W., & Parajuli, R. (2018). Radiation-associated angiosarcoma of the breast: A case report and literature review. Case Reports in Oncology, 11(1), 216-220.
Mali, B., Jarm, T., Snoj, M., Sersa, G., & Miklavcic, D. (2013 Jan 1). Antitumor effectiveness of electrochemotherapy: A systematic review and meta-analysis. European Journal of Surgical Oncology (eJsO), 39(1), 4-16.
Marchal, C., Weber, B., de Lafontan, B., Resbeut, M., Mignotte, H., & Cutuli, B. (1999). Nine breast angiosarcomas after conservative treatment for breast carcinoma: A survey from French comprehensive cancer centers. International Journal of Radiation, Oncology, Biology, Physics, 44, 113-119.
Monroe, A. T., Feigenberg, S. J., & Mendenhall, N. P. (2003). Angiosarcoma after breast-conserving therapy. Cancer: Interdisciplinary International Journal of the American Cancer Society, 97(8), 1832-1840.
Nagano, T., Yamada, Y., Ikeda, T., Kanki, H., Kamo, T., & Nishigori, C. (2007). Docetaxel: A therapeutic option in the treatment of cutaneous angiosarcoma: Report of 9 patients. Cancer: Interdisciplinary International Journal of the American Cancer Society, 110(3), 648-651.
Ogata, D., Yanagisawa, H., Suzuki, K., Oashi, K., Yamazaki, N., & Tsuchida, T. (2016). Pazopanib treatment slows progression and stabilizes disease in patients with taxane-resistant cutaneous angiosarcoma. Medical Oncology, 33(10), 116.
Penel, N., Bui, B. N., Bay, J. O., Cupissol, D., Ray-Coquard, I., Piperno-Neumann, S., … Isambert, N. (2008). Phase II trial of weekly paclitaxel for unresectableangiosarcoma: The ANGIOTAX study. Journal of Clinical Oncology, 26(32), 5269-5274.
Penel, N., Marréaud, S., Robin, Y. M., & Hohenberger, P. (2011). Angiosarcoma: State of the art and perspectives. Critical Reviews Oncology/Hematology, 80, 257-263.
Ray-Coquard, I. L., Domont, J., Tresch-Bruneel, E., Bompas, E., Cassier, P. A., Mir, O., … Penel, N. (2015). Paclitaxel given once per week with or without bevacizumab in patients with advanced angiosarcoma: A randomized phase II trial. Journal of Clinical Oncology, 33(25), 2797-2802.
Rols, M. P., Bachaud, J. M., Giraud, P., Chevreau, C., Roche, H., & Teissie, J. (2000). Electrochemotherapy of cutaneous metastases in malignant melanoma. Melanoma Research, 10(5), 468-474.
Schreiber, H., Barry, F. M., Russell, W. C., Macon, W. L., IV, Ponsky, J. L., & Pories, W. J. (1979). Stewart-Treves syndrome. A lethal complication of postmastectomy lymphedema and regional immunedeficiency. Archives of Surgery, 114, 82-85.
Scott, M. T., Portnow, L. H., Morris, C. G., Marcus, R. B., Jr., Mendenhall, N. P., Mendenhall, W. M., & Indelicato, D. J. (2013). Radiation therapy for angiosarcoma: The 35-year University of Florida experience. American Journal of Clinical Oncology, 36(2), 174-180.
Shin, J. Y., Roh, S. G., Lee, N. H., & Yang, K. M. (2017). Predisposing factors for poor prognosis of angiosarcoma of the scalp and face: Systematic review and meta-analysis. Head & Neck, 39(2), 380-386.
Sindhu, S., Gimber, L. H., Cranmer, L., McBride, A., & Kraft, A. S. (2017). Angiosarcoma treated successfully with anti-PD-1 therapy-a case report. Journal for Immunotherapy of Cancer, 5(1), 58.
Solari, N., Spagnolo, F., Ponte, E., Quaglia, A., Lillini, R., Battista, M., … Cafiero, F. (2014). Electrochemotherapy for the management of cutaneous and subcutaneous metastasis: A series of 39 patients treated with palliative intent. Journal of Surgical Oncology, 109(3), 270-274.
Stacchiotti, S., Palassini, E., Sanfilippo, R., Vincenzi, B., Arena, M. G., Bochicchio, A. M., … Casali, P. G. (2011). Gemcitabine in advanced angiosarcoma: A retrospective case series analysis from the Italian Rare Cancer Network. Annals of Oncology, 23(2), 501-508.
Stewart, F. W., & Treves, N. (1948). Lymphangiosarcoma in postmastectomy lymphedema: A report of six cases in elephantiasis chirurgica. Cancer, 1, 64-81.
Strobbe, L. J., Peterse, H. L., van Tinteren, H., Wijnmaalen, A., & Rutgers, E. J. (1998). Angiosarcoma of the breast after conservation therapy for invasive cancer, the incidence and outcome. An unforseen sequela. Breast Cancer Research and Treatment, 47, 101-109.
Trofymenko, O., & Curiel-Lewandrowski, C. (2018). Surgical treatment associated with improved survival in patients with cutaneous angiosarcoma. Journal of the European Academy of Dermatology and Venereology, 32(1), e29-e31.
Van Der Graaf, W. T., Blay, J. Y., Chawla, S. P., Kim, D. W., Bui-Nguyen, B., & Casali, P. G. (2012). Pazopanib for metastatic soft tissue sarcoma (PALETTE): A randomised, double blind, placebo-controlled phase 3 trial. The Lancet Oncology, 379, 1879-1886.
Vogt, T., Brockmeyer, N., Kutzner, H., & Schöfer, H. (2013). Brief S1 guidelines-Cutaneous angiosarcoma and Kaposi sarcoma. JDDG: Journal der Deutschen Dermatologischen Gesellschaft, 11(s3), 2-9.
Wada, N., Uchi, H., & Furue, M. (2018). Case of angiosarcoma of the scalp successfully controlled by eribulin. The Journal of Dermatology, 45(1), 116-117.
Yap, J., Chuba, P. J., Thomas, R., Aref, A., Lucas, D., Severson, R. K., & Hamre, M. (2002). Sarcoma as a second malignancy after treatment for breast cancer. International Journal of Radiation Oncology, Biology, Physics, 52(5), 1231-1237.
Young, R. J., Brown, N. J., Reed, M. W., Hughes, D., & Woll, P. J. (2010). Angiosarcoma. The Lancet Oncology, 11, 983-991.
Zemanova, M., Machalekova, K., Sandorova, M., Boljesikova, E., Skultetyova, M., Svec, J., & Zeman, A. (2014). Clinical management of secondary angiosarcoma after breast conservation therapy. Reports of Practical Oncology & Radiotherapy, 19(1), 37-46.